



iTrack™ Canaloplasty to be Featured at the 2024 American Glaucoma Society (AGS) Annual Meeting

California, USA, January, 10 2024 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary **iTrack™ canaloplasty technology** will be featured in numerous presentations and posters during the official scientific program of the 2024 American Glaucoma Society (AGS) Annual Meeting, taking place in Huntington Beach, CA, February 29 – March 3, 2024.

The AGS is the preeminent glaucoma-focused society in the USA, comprising more than 1600 fellowship trained glaucoma specialists and scientists active in glaucoma research.

A summary of the AGS 2024 presentations and posters is included below:

Podium Presentation:

Keith Barton, MD (UK)

Multicenter Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity

Date: Thursday, February 29

Time: 9:41 - 10:41am

Top Poster Presentations:

Shamil Patel, MD (USA)

Canaloplasty Effectiveness Correlated with Viscoelastic Volume Delivered in Schlemm's Canal

Date: Friday, March 01

Time: 7:30 - 8:30am

Paul J. Harasymowycz, MD (Canada)

Canaloplasty performed with the iTrack microcatheter to reduce IOP in uncontrolled glaucoma eyes

Date: Friday, March 01

Time: 7:30 - 8:30am



Jessica Hsueh, MD (USA)

Performing ab-interno canaloplasty in PACG eyes across different stages of glaucoma severity

Date: Friday, March 01

Time: 7:30 - 8:30am

Mark J. Gallardo, MD (USA)

Standalone Ab-Interno Canaloplasty in Severe Uncontrolled Glaucoma Eyes: a Case Series: 36 Months results

Date: Friday, March 01

Time: 7:30 - 8:30am

e-Poster:

David Lubeck, MD (USA)

24-Month Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma

Ahmad A. Aref, MD, MBA, ABO (USA)

Efficacy of Canaloplasty via an Ab-interno Approach Combined with GATT in Patients with Severe Open Angle Glaucoma

Matthew S. Porter, MD (USA)

A Study of Cataract Surgery Combined with Canaloplasty and Microtrabecular Bypass Stent Surgery in Severe and 3+ medications Open Angle Glaucoma patients

Mahmoud A. Khaimi, MD (USA)

Ab-interno Canaloplasty in Primary Angle-Closure Spectrum

Nova Eye will provide additional peer-to-peer educational opportunities during the AGS 2023 Meeting at the Nova Eye Medical Exhibit, booth #26



ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

For additional information about canaloplasty and the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu